296 related articles for article (PubMed ID: 23730525)
1. Computer-Aided Approaches for Targeting HIVgp41.
Allen WJ; Rizzo RC
Biology (Basel); 2012 Aug; 1(2):311-38. PubMed ID: 23730525
[TBL] [Abstract][Full Text] [Related]
2. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.
McGee TD; Yi HA; Allen WJ; Jacobs A; Rizzo RC
Bioorg Med Chem Lett; 2017 Jul; 27(14):3177-3184. PubMed ID: 28558972
[TBL] [Abstract][Full Text] [Related]
3. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
4. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
5. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
6. High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
Liu S; Jiang S
Curr Pharm Des; 2004; 10(15):1827-43. PubMed ID: 15180543
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
8. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
9. HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
Liu S; Jing W; Cheung B; Lu H; Sun J; Yan X; Niu J; Farmar J; Wu S; Jiang S
J Biol Chem; 2007 Mar; 282(13):9612-9620. PubMed ID: 17276993
[TBL] [Abstract][Full Text] [Related]
10. Six-helix bundle completion in the distal C-terminal heptad repeat region of gp41 is required for efficient human immunodeficiency virus type 1 infection.
Liu D; Wang H; Yamamoto M; Song J; Zhang R; Du Q; Kawaguchi Y; Inoue JI; Matsuda Z
Retrovirology; 2018 Apr; 15(1):27. PubMed ID: 29609648
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
12. Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeat-C-terminal heptad repeat interactions and C-peptides' anti-HIV activity.
Zheng B; Wang K; Lu L; Yu F; Cheng M; Jiang S; Liu K; Cai L
AIDS; 2014 Jun; 28(9):1251-60. PubMed ID: 24625369
[TBL] [Abstract][Full Text] [Related]
13. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
He Y; Cheng J; Li J; Qi Z; Lu H; Dong M; Jiang S; Dai Q
J Virol; 2008 Jul; 82(13):6349-58. PubMed ID: 18417584
[TBL] [Abstract][Full Text] [Related]
14. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
Yu F; Lu L; Liu Q; Yu X; Wang L; He E; Zou P; Du L; Sanders RW; Liu S; Jiang S
Biochim Biophys Acta; 2014 May; 1838(5):1296-305. PubMed ID: 24388952
[TBL] [Abstract][Full Text] [Related]
15. Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors.
Geng X; Liu Z; Yu D; Qin B; Zhu Y; Cui S; Chong H; He Y
Viruses; 2019 Jul; 11(7):. PubMed ID: 31277353
[TBL] [Abstract][Full Text] [Related]
16. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
[TBL] [Abstract][Full Text] [Related]
17. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
18. The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.
Ouyang W; An T; Guo D; Wu S; Tien P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):613-20. PubMed ID: 23308369
[TBL] [Abstract][Full Text] [Related]
19. Refolding Dynamics of gp41 from Pre-fusion to Pre-hairpin States during HIV-1 Entry.
Lin M; Da LT
J Chem Inf Model; 2020 Jan; 60(1):162-174. PubMed ID: 31845803
[TBL] [Abstract][Full Text] [Related]
20. A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.
Su S; Wang Q; Xu W; Yu F; Hua C; Zhu Y; Jiang S; Lu L
AIDS; 2017 Apr; 31(7):885-894. PubMed ID: 28121713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
